Fate Therapeutics, Inc. (FATE)
NASDAQ: FATE · Real-Time Price · USD
1.340
-0.265 (-16.51%)
At close: Nov 12, 2026, 4:00 PM EST
1.280
-0.060 (-4.48%)
After-hours: Nov 12, 2026, 7:59 PM EST

Fate Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
4.756.6513.6363.5396.355.85
Revenue Growth
-33.45%-51.24%-78.55%-34.03%72.44%77.66%
Cost of Revenue
91.991.9118.53157.19320.45215.52
Gross Profit
-87.15-85.25-104.9-93.65-224.15-159.67
Selling, General & Admin
51.9561.3590.6496.8684.2357.32
Operating Expenses
42.8561.3590.6496.8684.2357.32
Operating Income
-130-146.6-195.54-190.51-308.39-216.99
Interest & Investment Income
7.0511.0517.2917.195.841.31
Other Non Operating Income (Expenses)
-0.380.346.737.320.323.53
EBT Excluding Unusual Items
-123.33-135.22-171.53-166.03-282.22-212.15
Merger & Restructuring Charges
-1.1-1.1----
Asset Writedown
---14.74---
Other Unusual Items
---5.10.5-
Pretax Income
-124.43-136.32-186.26-160.93-281.72-212.15
Net Income
-124.43-136.32-186.26-160.93-281.72-212.15
Net Income to Common
-124.43-136.32-186.26-160.93-281.72-212.15
Net Income Growth
------
Shares Outstanding (Basic)
121119114989795
Shares Outstanding (Diluted)
121119114989795
Shares Change
2.04%4.49%15.52%1.64%2.19%15.00%
EPS (Basic)
-1.03-1.15-1.64-1.64-2.91-2.24
EPS (Diluted)
-1.03-1.15-1.64-1.64-2.91-2.24
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-106.97-112.04-123.6-138.42-283.77-213.57
Free Cash Flow Per Share
-0.89-0.94-1.09-1.41-2.93-2.25
Gross Margin
----147.41%-232.77%-285.92%
Operating Margin
-2736.88%-2205.90%-1434.52%-299.86%-320.24%-388.56%
Profit Margin
-2619.64%-2051.08%-1366.46%-253.30%-292.55%-379.89%
Free Cash Flow Margin
-2252.08%-1685.78%-906.79%-217.87%-294.68%-382.43%
EBITDA
-118.56-133.7-176.58-172.23-294.63-211.14
EBITDA Margin
----271.09%--
D&A For EBITDA
11.4412.918.9618.2813.765.85
EBIT
-130-146.6-195.54-190.51-308.39-216.99
EBIT Margin
----299.86%--
SEC Filings: 10-K · 10-Q